“The assumption that we each have a single genome turns out to be off by a trillion-fold,” said Geoffrey von Maltzahn, Ph.D., Co-Founder and Chief Executive Officer of Quotient Therapeutics and General Partner, Flagship Pioneering. “All cells accumulate random genetic changes in their DNA, resulting in trillions of unique genomes in the body. Some genetic changes make a cell resistant or vulnerable to disease, while others can cause disease. We started Quotient to study the natural genetics library inside every tissue, discover gene variants that are beneficial, neutral, or disease-causing, and to harness that knowledge to develop the medicines of tomorrow.”

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that

Yourgene’s LightBench is an automated electrophoresis instrument, powered by Ranger® Technology. This platform uses a patent-protected, machine-vision algorithm to interpret and control gel electrophoresis in real time. It delivers accurate size selection for human genomic DNA and includes the ability to perform fragment length analysis for additional quality control.

The BeVigilant OraFusion System stands out as an innovative device in the oral cancer domain, serving as a critical tool in oral cancer detection by identifying specific salivary biomarkers and integrating intelligent software to evaluate clinical risk factors.